申请人:eFFECTOR Therapeutics, Inc.
公开号:US20190119256A1
公开(公告)日:2019-04-25
The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I or Formula II, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof.
For Formula I compounds X
1
, X
2
, X
3
, X
4
, X
5
, Y
1
, Y
2
, R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, R
7
, R
8
, R
9
, R
10
, R
11
, R
12
and R
13
are as defined in the specification. The inventive Formula I and Formula II compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.
本发明提供了按照式I或式II或其立体异构体、互变异构体或药学上可接受的盐合物的化合物的合成、药学上可接受的配方和用途。对于式I化合物,X1、X2、X3、X4、X5、Y1、Y2、R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12和R13在说明书中定义。本发明的式I和式II化合物是Mnk的抑制剂,在许多治疗应用中发现其有用性,包括但不限于治疗炎症和各种癌症。